Download MendeleyDiscovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3K delta inhibitors.
Qin, L.Y., Ruan, Z., Cherney, R.J., Dhar, T.G., Neels, J., Weigelt, C.A., Sack, J.S., Srivastava, A.S., Cornelius, L.A., Tino, J.A., Stefanski, K., Gu, X., Xie, J., Susulic, V., Yang, X., Yarde-Chinn, M., Skala, S., Bosnius, R., Goldstein, C., Davies, P., Ruepp, S., Salter-Cid, L., Bhide, R.S., Poss, M.A.(2017) Bioorg Med Chem Lett 27: 855-861
- PubMed: 28108251
- DOI: https://doi.org/10.1016/j.bmcl.2017.01.016
- Primary Citation of Related Structures:
5UBR, 5UBT - PubMed Abstract:
As demonstrated in preclinical animal models, the disruption of PI3Kδ expression or its activity leads to a decrease in inflammatory and immune responses. Therefore, inhibition of PI3Kδ may provide an alternative treatment for autoimmune diseases, such as RA, SLE, and respiratory ailments. Herein, we disclose the identification of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors. The lead compound demonstrated efficacy in an in vivo mouse KLH model.
Organizational Affiliation:
Bristol-Myers Squibb, Rt. 206 & Province Line Road, Princeton, NJ 08540, USA. Electronic address: lan-ying.qin@bms.com.
